×
News Home

Should You Accumulate aTyr Pharma Inc (LIFE) in Biotechnology Industry?

Monday, September 27, 2021 10:14 AM | InvestorsObserver Analysts
Should You Accumulate aTyr Pharma Inc (LIFE) in Biotechnology Industry?

A rating of 100 puts aTyr Pharma Inc (LIFE) near the top of the Biotechnology industry according to InvestorsObserver. aTyr Pharma Inc's score of 100 means it scores higher than 100% of stocks in the industry. aTyr Pharma Inc also received an overall rating of 85, putting it above 85% of all stocks. Biotechnology is ranked 79 out of the 148 industries.

Overall Score - 85
LIFE has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on LIFE!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 85 would rank higher than 85 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With aTyr Pharma Inc Stock Today?

aTyr Pharma Inc (LIFE) stock has gained 1.85% while the S&P 500 is lower by -0.12% as of 10:13 AM on Monday, Sep 27. LIFE is higher by $0.19 from the previous closing price of $10.25 on volume of 131,387 shares. Over the past year the S&P 500 is higher by 32.77% while LIFE is higher by 185.25%. LIFE lost -$2.29 per share the over the last 12 months. Click Here to get the full Stock Report for aTyr Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App